Hostname: page-component-848d4c4894-2xdlg Total loading time: 0 Render date: 2024-06-21T00:48:35.609Z Has data issue: false hasContentIssue false
  • English
  • Français

Probing the Function of 5-HT1B/1D Receptors in Psychiatric Patients

Published online by Cambridge University Press:  07 November 2014

Richard Whale  and
Philip J. Cowen
Get access Rights & Permissions [Opens in a new window]

Abstract

Pharmacological challenge tests provide a method of assessing the functional responsiveness of serotonin (5-HT) receptor subtypes in the human brain. A number of selective agonist ligands for the 5-HT1B/1D receptor are available for human use; however, these compounds do not distinguish between 5-HT1B and 5-HT1D receptors, which is somewhat of a disadvantage. Acute administration of sumatriptan, rizatriptan, and zolmitriptan all increase plasma growth hormone in healthy subjects, possibly via activation of postsynaptic 5-HT1D receptors. This response is blunted in major depression. Sumatriptan lowers plasma prolactin, perhaps via activation of presynaptic 5-HT1B receptors. This response is not altered during repeated treatment with selective serotonin reuptake inhibitors (SSRIs), suggesting that 5-HT1B receptors retain the ability to restrain 5-HT outflow during short-term SSRI treatment.

Type
Feature Article
Information
CNS Spectrums , Volume 3 , Issue 8: Serotonin Subsystems , September 1998 , pp. 40 - 45
Copyright
Copyright © Cambridge University Press 1998

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Cowen, PJ. Serotonin receptor subtypes in depression: evidence from studies in neuroendocrine regulation. Clin Neuropharmacol. 1993;16(suppl):S6–S18.Google Scholar
2.Wilkinson, LO, Middlemiss, DN. The autoregulation of 5-HT release from nerve terminals in vitro. In: Bradley, PB, Handley, SL, Cooper, SJ, Key, BJ, Barnes, NM, Coote, JH, eds. Serotonin, CNS Receptors and Brain Function. Oxford, England: Pergamon; 1992:1–11.Google Scholar
3.Kennett, GA, Dourish, CT, Curzon, G. 5-HT1B agonists induce anorexia at a postsynaptic site. Eur J Pharmacol. 1987;141:429–435.Google Scholar
4.Lee, MD, Simansky, KJ. CP-94,253: selective serotonin IB (5-HT1B) agonist that promotes satiety. Psychopharmacobgy. 1997;131:264–270.Google Scholar
5.Hatcher, JP, Slade, PD, Roberts, C, Hagan, JJ. 5-HT1D receptors mediate SKF-99101H induced hypothermia in the guinea-pig. J Psychopharmacol (Oxf). 1995;9:234–241.Google Scholar
6.Hagan, JJ, Slade, PD, Caster, L, Jeffrey, P, Hatcher, JP, Middlemiss, DN. Stimulation of 5-HT1B receptors causes hypothermia in the guinea pig. Eur J Pharmacol. 1997;331:169–174.Google Scholar
7.Dallas, FA, Dixon, CN, McCulloch, RJ, Saynor, DA. The kinetics of 14 C-GR43175 in rat and dog. Cephalalgia. 1989;9(suppl):53–56.Google Scholar
8.Goadsby, PJ, Edvinsson, L. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin 5-HT1D receptor agonist 311C90. Headache. 1994;34:394–399.Google Scholar
9.Humphrey, PP, Feniuk, W, Marriott, AS, Tanner, RJ, Jackson, MR, Tucker, ML. Preclinical studies on the antimigraine drug, sumatriptan. Eur Neurol. 1991;31:282–290.Google Scholar
10.Sharpley, AL, Cowen, PJ. Effect of pharmacologic treatments on the sleep of depressed patients. Biol Psychiatry. 1995;37:85–98.CrossRefGoogle ScholarPubMed
11.Park, SB, Coull, JT, McShane, RH, et al.Tryptophan depletion in normal volunteers produces selective impairments in learning and memory. Neuropharmacology. 1994;33:575–588.Google Scholar
12.Walsh, AES, Smith, KA, Oldman, AD, Williams, C, Goodall, EM, Cowen, PJ. M-Chlorophenylpiperazine decreases food intake in a test meal. Psychopharmacology (Bed). 1994;116:120–122.Google Scholar
13.Herdman, JRE, Delva, NJ, Hockney, RA, Campling, GM, Cowen, PJ. Neuroendocrine effects of sumatriptan. Psychopharmacology. 1994;113:561–564.Google Scholar
14.Boeles, S, Williams, C, Campling, GM, Goodall, EM, Cowen, PJ. Sumatriptan decreases food intake and increases plasma growth hormone in healthy women. Psychopharmacology. 1997;129:179–182.CrossRefGoogle ScholarPubMed
15.Sciberras, DG, Polvino, WJ, Gertz, BJ, et al.Initial human experience with MK-462 (rizatriptan): a novel 5-HT1D agonist. Br J Pharmacol. 1997;43:49–54.Google Scholar
16.Facchinetti, F, Nappi, RE, Sanees, G, Fioroni, L, Nappi, G, Genazzani, AR. The neuroendocrine effects of sumatriptan, a specific ligand for 5-HT1–like receptors. Clin Endocrinol (Oxf). 1994;40:211–214.Google Scholar
17.Franceschini, R, Cataldi, A, Garibaldi, A, et al.The effects of sumatriptan on pituitary secretion in man. Neuropharmacology. 1994;33:235–239.Google Scholar
18.Markianos, M, Lykouras, L, Hatzimanolis, J, Bistolaki, E. Effects of the serotonin receptor agonist sumatriptan on hormonal plasma levels in healthy and depressed subjects: a placebo controlled study. Neuroendocrinology. 1994;16:65–71. Letter.Google Scholar
19.Whale, R, Cowen, PJ. Sumatriptan lowers plasma prolactin in healthy female volunteers. Psychopharmacology. 1998;137:203–204.Google Scholar
20.Eckland, DJ, Entwisle, SJ, Fowler, PA, et al.The effects of sumatriptan, a 5-HT1-like agonist on pituitary adrenal function in healthy volunteers. Br J Clin Pharmacol. 1992;33:538.Google Scholar
21.Peroutka, SJ, McCarthy, BG. Sumatriptan (GR43175) interacts selectively with 5-HT1B and 5-HT1D binding sites. Eur J Pharmacol. 1989;163:133–136.Google Scholar
22.Martin, GR, Robertson, AD, MacLennan, SJ, et al.Receptor specificity and trigémino-vascular inhibitory action of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan). Br J Pharmacol. 1997;121:157–164.Google Scholar
23.Peroutka, SJ. Pharmacological differentiation of human 5-HT1B and 5-HT1D receptors. Biol Signals. 1994;3:217–222.Google Scholar
24.Van de Kar, LD. Neuroendocrine pharmacology of serotonergic (5-HT) neurones. Annu Rev Pharmacol Toxicol. 1991;31:289–320.Google Scholar
25.Johnson, KW, Schaus, JM, Durkin, MM, et al.5-HT1E receptor agonists inhibit neurogenic durai inflammation in guinea pigs. Neuroreport. 1997;8:2237–2240.Google Scholar
26.Smith, KA, Cowen, PJ. Depression: neurobiological, psy-chopathological and therapeutic advances. In: Honig, A, van Praag, HM, eds. Serotonin and Depression. Chichester, England: John Wiley & Sons; 1997:129–146.Google Scholar
27.Lesch, KP. 5-HT1A receptor responsivity in anxiety disorders and depression. Prog Neuropsychopharmacol Biol Psychiatry. 1992;15:723–733.Google Scholar
28.Meltzer, HY, Maes, M. Effects of ipsapirone on plasma Cortisol and body temperature in major depression. Biol Psychiatry. 1995;38:450–457.Google Scholar
29.Yatham, LN, Raymond, WL, Athanasios, PZ. Growth hormone response to sumatriptan (5-HT1D agonist) challenge in seasonal affective disorder: effects of light therapy. Biol Psychiatry. 1997;42:24–29.CrossRefGoogle ScholarPubMed
30.Yatham, LN, Athanasios, PZ, Lam, RW, Tam, E, Shiah, I-S. Sumatriptan-induced growth hormone release in patients with major depression, mania and normal controls. Neuropsychopharmacology. 1997;17:258–263.Google Scholar
31.Cleare, AJ, Murray, RM, Sherwood, RA, O'Keane, V. Abnormal 5-HT1D receptor function in major depression: a neuropharmacological challenge study using sumatriptan. Psychol Med. 1998;28:295–300.Google Scholar
32.LaPorta, LD. Recurrent depression after sumatriptan administration for treatment of migraine. J Clin Psychopharmacol. 1995;15:81–82.CrossRefGoogle ScholarPubMed
33.Smith, KA, Fairburn, CG, Cowen, PJ. Relapse of depression after rapid depletion of tryptophan. Lancet. 1997;349:915–919.Google Scholar
34.Zohar, J, Mueller, EA, Insel, TR, Zohar-Kadouch, RC, Murphy, DL. Serotonin responsivity in obsessive-compulsive disorder. Arch Gen Psychiatry. 1987;44:946–951.Google Scholar
35.Zohar, J. Is 5-HT1D involved in obsessive compulsive disorder? Journal of European College of Neuropsychopharmacology. 1996;6(suppl 4):S4–54. Abstract.Google Scholar
36.Ho Pian, KL, Westenberg, HGM, van Megen, HJGM, den Boer, JA. Sumatriptan (5-HTin receptor agonist) does not exacerbate symptoms in obsessive compulsive disorder. Psychopharmacology. 1998. In press.Google Scholar
37.Moret, C, Briley, M. Serotonin autoreceptor subsensitivity and antidepressant activity. Eur J Pharmacol. 1990;180:351–356.Google Scholar
38.Blier, P, Bouchard, C. Modulation of 5-HT release in the guinea-pig brain following long-term administration of antidepressant drugs. Br J Pharmacol. 1994;113:485–495.Google Scholar
39.Wing, Y-K, Clifford, EM, Sheehan, BD, Campling, GM, Hockney, RA, Cowen, PJ. Paroxetine treatment and the prolactin response to sumatriptan. Psychopharmacology. 1996;124:377–379.Google Scholar
40.Gundlah, C, Hjorth, S, Auerbach, SB. Autoreceptor antagonists enhance the effect of the reuptake inhibitor citalo-pram on extracellular 5-HT: this effect persists after repeated citalopram treatment. Neuropharmacology. 1997;36:475–482.Google Scholar
41.American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd Ed. Revised. Washington, DC: American Psychiatric Press; 1980.Google Scholar